Search results for PX-TA1308

Dupilumab Biosimilar – Anti-IL4R, CD124 mAb – Research Grade, ProteoGenix, PX-TA1308

Description of Dupilumab Biosimilar - Anti-IL4R, CD124 mAb - Research Grade General information on Anti-IL4R/CD124[Homo sapiens] (Dupilumab) Monoclonal Antibody Dupilumab is a human monoclonal antibody of isotype IgG4 that targets the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. Dupilumab inhibits the signaling pathway of interleukins, that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reaction, and rhinosinusitis.Dupilumab has been marketed under the trade name Dupixent. It has been also investigated for the treatment of diseases driven by allergic reactions or type 2 inflammation, such as pediatric atopic dermatitis, eosinophilic esophagitis, and chronic obstructive pulmonary disease.